Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19476349 | 0.90 | PIK3CA (0.37) | KDM4EALDH1A1TP53HPGDHSD17B10 | |
| SCHEMBL10117911 | 0.79 | PIK3CD (0.43) | HTR6NOTUML3MBTL1 | |
| SCHEMBL28301646 | 0.76 | ENPP3 (0.34) | MCL1 | |
| SCHEMBL15202439 | 0.76 | GSK3B (0.34) | HTR6GSK3B | |
| SCHEMBL20914435 | 0.73 | AGXT (0.35) | KDM4EALDH1A1HPGDHSD17B10MCL1 | |
| SCHEMBL12903453 | 0.72 | BRD4 (0.46) | KDM4EHTR6GSK3BMCL1PAX8 | |
| SCHEMBL19476354 | 0.72 | NR1H2 (0.37) | — | |
| SCHEMBL19463917 | 0.71 | MAOA (0.46) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL14006351 | 0.71 | MCL1 (0.41) | KDM4EALDH1A1TP53HPGDHSD17B10 | |
| SCHEMBL30071051 | 0.70 | NR1H2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| CN-115650985-A | Heterocyclic compounds as RET kinase inhibitors | 癌症研究科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11548896-B2 | Heterocyclic compounds as RET kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-01-10 | — | — | US | disclosed |
| CN-109195972-B | Heterocyclic compounds as RET kinase inhibitors | 癌症研究科技有限公司 | 2022-10-28 | — | — | CN | disclosed |
| EP-3960180-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Cancer Research Technology Limited (GB) | 2022-03-02 | — | — | EP | disclosed |
| EP-3442980-B1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-06-09 | — | — | EP | disclosed |
| US-20210155628-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECH LTD (GB) | 2021-05-27 | — | — | US | disclosed |
| US-10954241-B2 | Heterocyclic compounds as ret kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20190106425-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155628-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | KDM4E 977/4885ALDH1A1 3019/4885TP53 703/4885 |
| US-20190106425-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, REL, BCR | KDM4E 977/4885ALDH1A1 3019/4885TP53 703/4885 |
| US-11548896-B2 | Heterocyclic compounds as RET kinase inhibitors | RET, REL, BCR | KDM4E 977/4885ALDH1A1 3019/4885TP53 703/4885 |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | KDM4E 977/4885ALDH1A1 3019/4885TP53 703/4885 |
| US-10954241-B2 | Heterocyclic compounds as ret kinase inhibitors | RET, REL, BCR | KDM4E 977/4885ALDH1A1 3019/4885TP53 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.